COMP360 Psilocybin Treatment
Treatment-Resistant Depression (TRD)
Key Facts
About Compass Pathways
Compass Pathways is a clinical-stage biotech focused on reimagining mental health care by developing psilocybin therapy for conditions with high unmet need. Its core asset, COMP360, is being evaluated in a pivotal Phase 3 program for treatment-resistant depression, with parallel Phase 2 studies in PTSD and anorexia. The company operates with a patient-centric mission, emphasizing scientific rigor, broad accessibility, and collaboration to advance evidence-based psychedelic treatments.
View full company profileAbout Compass Pathways
Compass Pathways is a clinical-stage biotech focused on reimagining mental health care by developing psilocybin therapy for conditions with high unmet need. Its core asset, COMP360, is being evaluated in a pivotal Phase 3 program for treatment-resistant depression, with parallel Phase 2 studies in PTSD and anorexia. The company operates with a patient-centric mission, emphasizing scientific rigor, broad accessibility, and collaboration to advance evidence-based psychedelic treatments.
View full company profileAbout Compass Pathways
Compass Pathways is a clinical-stage biotech focused on reimagining mental health care by developing psilocybin therapy for conditions with high unmet need. Its core asset, COMP360, is being evaluated in a pivotal Phase 3 program for treatment-resistant depression, with parallel Phase 2 studies in PTSD and anorexia. The company operates with a patient-centric mission, emphasizing scientific rigor, broad accessibility, and collaboration to advance evidence-based psychedelic treatments.
View full company profileTherapeutic Areas
Other Treatment-Resistant Depression (TRD) Drugs
| Drug | Company | Phase |
|---|---|---|
| SPN-820/821 | Supernus Pharmaceuticals | Phase 2 |
| BHV-2100 (mGluR2/3 NAM) | Biohaven | Phase 1 |
| PCN-101 (R-ketamine) | atai Life Sciences | Phase 2 |
| VLS-01 (DMT) | atai Life Sciences | Phase 1 |
| Salvianolic Acid B | atai Life Sciences | Preclinical |
| GH001 | GH Research | Phase 2b |
| BMB-101 | Bright Minds Biosciences | Phase 2 |
| MW-101 | MindWalk Holdings | Phase 2 |
| NPH-101 | Neuphoria Therapeutics | Phase 1/2 |
| CYC-126 | Cyclerion Therapeutics | Phase 2 |